



## **PRESS RELEASE**

### **Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations**

*BETHLEHEM, PA, (April 28, 2011)* - Particle Sciences Inc. (PSI), a leading pharmaceutical CRO, and Celanese EVA Performance Polymers, a leading supplier of ethylene vinyl acetate (EVA) into pharmaceutical applications, are working together to streamline the development of drug-eluting devices. Building on years of collaboration, Particle Sciences and Celanese EVA Performance Polymers are working to provide Particle Sciences with preferred access to VitalDose™ EVA polymer in early stage projects.

According to Andrew Loxley, Particle Sciences' Director of New Technologies, "With combination products, devices that deliver drugs, there are multiple parties involved including the innovator, the API supplier, the development group and the polymer supplier. All parties want to ensure a quality product. Particle Sciences and Celanese EVA Performance Polymers have been collaborating for a number of years and, because of that relationship, are now in a position to expedite the process."

With this collaboration, there is a highly streamlined process by which Particle Sciences obtains access to use Celanese EVA polymers in early development efforts. Jamie Beggs, Marketing Development Manager, Celanese EVA Performance Polymers, states, "We are committed to becoming the premier EVA excipient producer and have been providing EVA technology for medical applications for years. Our VitalDose brand delivers the reliable performance required for pharma applications combined with in-depth technical expertise and comprehensive regulatory knowledge. This partnership is a testament to the degree to which we have developed confidence in Particle Sciences' capabilities and their focus on quality. With their capabilities in prototyping, characterization, experience with controlled and highly potent substances and cGMP facilities, they have consistently delivered innovation to our customers."

Robert Lee, Vice President Pharmaceutical Development at Particle Sciences adds, "Combination products have unique development challenges. For each project, it's important that we start with an open mind as to polymer choice and device architecture. For our EVA needs, we are extremely pleased to be aligned with Celanese EVA Performance Polymers, the group we believe to be most appropriately addressing this market."



# PARTICLE SCIENCES

DRUG DEVELOPMENT SERVICES

**Particle Sciences Inc.** is an integrated provider of drug development services. Particle Sciences focuses on emulsions, gels, particulates and drug/device combination products with additional specialized capabilities in topical and mucosal drug delivery. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visit [www.particlesciences.com](http://www.particlesciences.com), email [info@particlesciences.com](mailto:info@particlesciences.com) or contact us at (610) 861-4701 for information.

**Celanese EVA Performance Polymers Inc.** is a North American leader in developing products and application technology to improve performance, create value and drive innovation in a broad range of industrial and consumer end-use applications including flexible packaging, thermal lamination film, hot melt adhesive, USP class VI medical products and photovoltaic cells. The business has manufacturing facilities in Edmonton, Canada, and is supported by expert technical service. More information about Celanese EVA Performance Polymers Inc. is available at [www.celanese-EVA.com](http://www.celanese-EVA.com).

Contact: Maureen Cochran  
[mcochran@particlesciences.com](mailto:mcochran@particlesciences.com)